Omar K. Siddiqi MD

Assistant Professor, Cardiovascular Medicine

88 E. Newton St | (617) 638-8760
Omar Siddiqi
Sections

Cardiovascular Medicine

Centers

Amyloidosis Center

Biography

Omar Siddiqi, MD is an Assistant Professor of Medicine in Cardiovascular Medicine at the Boston University School of Medicine, and he is the Program Director of the Cardiovascular Medicine Fellowship Program. As director of the cardiology fellowship curriculum, he is credited with developing an academic half day for cardiovascular medicine fellows, developing an echocardiography curriculum utilizing the CAE echocardiography simulator housed in the Solomont Simulation Center, and starting an Imaging Show and Tell conference. These efforts have been recognized with two Cardiovascular Medicine Fellowship Faculty Teaching Awards which he won in 2015 and 2018. At the Boston University School of Medicine, he serves as co-director of the second year medical school cardiovascular pathophysiology module. His research interests in medical education include the development of simulation-based curricula and the integration of team-based learning (TBL) in teaching ECGs. His clinical interests include cardiac amyloidosis and echocardiography, and he is an attending cardiologist in the BU Amyloidosis Center. His clinical research interests are around the assessment of novel therapies for the treatment of cardiac amyloidosis. He has served as Clinical Investigator of five studies, including two currently.

Education

Medicine-Internal, MD, Washington University School of Medicine, 2007

Biology, BS, University of Rhode Island, 2003

Publications

Published on 5/1/2021

Benbrahim M, Norman K, Sanchorawala V, Siddiqi OK, Hughes D. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis. J Cardiovasc Pharmacol. 2021 05 01; 77(5):544-548. PMID: 33657048.

Published on 12/15/2020

Lohrmann G, Patel MA, Brauneis D, Sanchorawala V, Sarosiek S, Vellanki N, Siddiqi OK, Ruberg FL, Gopal DM. Left Atrial Mechanics Associates With Paroxysmal Atrial Fibrillation in Light-Chain Amyloidosis Following Stem Cell Transplantation. JACC CardioOncol. 2020 Dec; 2(5):721-731. PMID: 33511355.

Published on 10/28/2020

Ruberg FL, Siddiqi OK. In Search of the Holy Grail: Evidence of Amyloid Fibril Regression in ATTR Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2021 01; 14(1):200-202. PMID: 33129738.

Published on 3/17/2020

Ruberg FL, Siddiqi OK. Hepatocyte Growth Factor and Cardiac Amyloidosis. JACC CardioOncol. 2020 Mar; 2(1):67-69. PMID: 32647833.

Published on 3/1/2020

Ruberg FL and Siddiqi OK. Hepatocyte Growth Factor and Cardiac Amyloidosis. JACC: Cardio Oncology. 2020; 2(1):67-69.

Published on 12/2/2019

Lohrmann G, Pipilas A, Mussinelli R, Gopal DM, Berk JL, Connors LH, Vellanki N, Hellawell J, Siddiqi OK, Fox J, Maurer MS, Ruberg FL. Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis. J Card Fail. 2020 Sep; 26(9):753-759. PMID: 31805416.

Published on 10/1/2019

Gopal DM, Ruberg FL, Siddiqi OK. Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis. Curr Heart Fail Rep. 2019 10; 16(5):180-188. PMID: 31520266.

Published on 1/21/2019

Phull P, Sanchorawala V, Brauneis D, Sloan JM, Siddiqi OK, Quillen K, Sarosiek S. High-dose melphalan and autologous peripheral blood stem cell transplantation in patients with AL amyloidosis and cardiac defibrillators. Bone Marrow Transplant. 2019 08; 54(8):1304-1309. PMID: 30664726.

Published on 7/27/2018

Pandey S, Siddiqi OK. Tc-99m pyrophosphate imaging for transthyretin cardiac amyloidosis: Importance of estimation of cancer risk with the modality. J Nucl Cardiol. 2020 02; 27(1):225-227. PMID: 30054791.

Published on 5/1/2018

Siddiqi OK, Sanchorawala V, Ruberg FL. Echocardiography and Survival in Light Chain Cardiac Amyloidosis: Back to Basics. Circ Cardiovasc Imaging. 2018 05; 11(5):e007826. PMID: 29752394.

View full list of 20 publications.